Individualized long-term chemotherapy for recurrent ovarian cancer after failing high-dose treatment

Anti-cancer Drugs
M BreidenbachC M Kurbacher

Abstract

Chemotherapy for recurrent ovarian carcinoma (ROC) produces response rates of 10-80% depending on the prevalence of platinum resistance. Most patients relapse within 1 year and median progression-free survival is generally no more than 6 months. Newly developed ATP chemosensitivity assays (ATP-TCA) offer the opportunity for individualized therapy and have shown promising results compared to standard regimens. We report on an unusual case of long-term survival in a patient with stage III c ovarian cancer failing postoperative platinum-based high-dose treatment who subsequently underwent repeated chemotherapy over a period of 4 years. The chemotherapy protocol was selected by pretherapeutic ex vivo ATP-based chemosensitivity testing of autologous tumor tissue. To our knowledge, this is one of the few cases of ROC in which partial remissions using conventionally dosed chemotherapy were achieved repeatedly despite a unfavorable relapse-free interval after high-dose chemotherapy for primary disease. We conclude that ATP-TCA-directed chemotherapy for ROC can select active and tolerable regimens even in difficult therapeutic situations in which no standards recommendation exists.

References

Oct 19, 1994·Journal of the National Cancer Institute·B LundJ P Neijt
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·B EjlertsenB Kristensen
Jun 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W ten Bokkel HuininkJ F Heron
Feb 20, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P G RoseH D Homesley
Mar 13, 1999·Seminars in Oncology Nursing·K G O'Connor

❮ Previous
Next ❯

Citations

Aug 1, 2005·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Shin Myung KangJoo-Hang Kim
Feb 3, 2009·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·Y B ChoH-K Chun
May 4, 2004·Journal of the Society for Gynecologic Investigation·Maryann B FlickGil Mor
Nov 26, 2003·International Journal of Cancer. Journal International Du Cancer·Rosalyn D BlumenthalDavid Modrak

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.